Related Experiment Videos

NASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challenges

Naim Alkhouri¹

¹Texas Liver Institute, UT Health San Antonio, San Antonio, Texas, USA.

Expert Opinion on Investigational Drugs

|January 28, 2020

Abstract

No abstract available in PubMed .

Keywords:

NAFLD biomarkers elafibranor firsocostat hepatocellular carcinoma liver fibrosis nonalcoholic fatty liver disease nonalcoholic steatohepatitis obeticholic acid pioglitazone

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Histologic Features and Clinical Outcomes of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease.

JAMA·2026

International expert panel review for the use of resmetirom and semaglutide in the management of MASH-related fibrosis: clinical practice update.

Gut·2026

Gender differences in stigma and care avoidance among people living with MASLD: an international survey.

JHEP reports : innovation in hepatology·2026

Detection of Potential Metabolic and Alcohol-Associated Liver Disease and Alcohol-Associated Liver Disease Using Phosphatidylethanol in a Large Multicenter Metabolic Dysfunction-Associated Steatohepatitis Trial Screening Cohort.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026

Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH.

Hepatology (Baltimore, Md.)·2026

Global multicenter validation of noninvasive fibrosis assessment pathways in MetALD and ALD.

Hepatology communications·2026

See all related articles